Monopar Therapeutics (MNPR) Research & Development (2017 - 2020)

Monopar Therapeutics' Research & Development history spans 4 years, with the latest figure at $1.6 million for Q4 2020.

  • For Q4 2020, Research & Development rose 179.62% year-over-year to $1.6 million; the TTM value through Dec 2020 reached $4.1 million, up 106.51%, while the annual FY2024 figure was $4.0 million, 28.57% down from the prior year.
  • Research & Development for Q4 2020 was $1.6 million at Monopar Therapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.6 million in Q4 2020 and bottomed at $133736.0 in Q1 2017.
  • The 4-year median for Research & Development is $336850.5 (2019), against an average of $534657.9.
  • The largest YoY upside for Research & Development was 471.27% in 2020 against a maximum downside of 58.78% in 2020.
  • A 4-year view of Research & Development shows it stood at $309315.0 in 2017, then soared by 68.43% to $520982.0 in 2018, then grew by 12.05% to $583778.0 in 2019, then skyrocketed by 179.62% to $1.6 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Research & Development are $1.6 million (Q4 2020), $1.3 million (Q3 2020), and $832503.0 (Q2 2020).